| Literature DB >> 22611347 |
M A Salam1, M A Affan, Ramkrishna Saha, Fasihuddin B Ahmad, Norrihan Sam.
Abstract
Five new organotin(IV) complexes of 2-hydroxyacetophenone-2-methylphenylthiosemicarbazone [H(2)dampt, (1)] with formula [RSnCl(n-1)(dampt)] (where R = Me, n = 2 (2); R = Bu, n = 2 (3); R = Ph, n = 2 (4); R = Me(2), n = 1 (5); R = Ph(2), n = 1 (6)) have been synthesized by direct reaction of H(2)dampt (1) with organotin(IV) chloride(s) in absolute methanol. The ligand (1) and its organotin(IV) complexes (2-6) were characterized by CHN analyses, molar conductivity, UV-Vis, FT-IR, (1)H, (13)C, and (119)Sn NMR spectral studies. H(2)dampt (1) is newly synthesized and has been structurally characterized by X-ray crystallography. Spectroscopic data suggested that H(2)dampt (1) is coordinated to the tin(IV) atom through the thiolate-S, azomethine-N, and phenoxide-O atoms; the coordination number of tin is five. The in vitro antibacterial activity has been evaluated against Staphylococcus aureus, Enterobacter aerogenes, Escherichia coli, and Salmonella typhi. The screening results have shown that the organotin(IV) complexes (2-6) have better antibacterial activities and have potential as drugs. Furthermore, it has been shown that diphenyltin(IV) derivative (6) exhibits significantly better activity than the other organotin(IV) derivatives (2-5).Entities:
Year: 2012 PMID: 22611347 PMCID: PMC3352140 DOI: 10.1155/2012/698491
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Synthesis of 2-hydroxyacetophenone-2-methylphenylthiosemicarbazone (H2dampt) ligand (1).
Scheme 2Reaction scheme for the synthesis of organotin(IV) complexes (2–6).
Figure 1The molecular structure of H2dampt (1) showing the atom-labelling scheme and displacement ellipsoids at the 50% probability level.
Summary of crystal data and structure refinement parameters for ligand (1).
| Compound | H2dampt ( |
|---|---|
| Empirical formula | C16H17N3OS |
| Formula weight | 299.39 |
| Temperature (K) | 100 (2) |
| Wavelength (Å) | 0.71073 |
| Crystal system | Monoclinic |
| Space group |
|
| Unit cell dimensions | |
| a (Å) | 14.6966(8) |
| b (Å) | 7.3586(4) |
| c (Å) | 14.0926(8) |
|
| 90.00 |
|
| 94.358(5) |
|
| 90.00 |
| Volume (Å3) | 1519.66(15) |
| Z | 4 |
| Calculated density (mg/m3) | 1.309 |
| Radiation type | Mo K∖a |
| F (000) | 632 |
| Crystal size (mm) | 0.30 × 0.1 × 0.05 |
| Crystal colour | Light-yellow |
| Scan range | 2.8–29.3 |
| Absorption coefficient ( | 0.225 |
| Max. and min. transm | 1.00 and 0.419 |
| Goodness of fit on F2 | 0.995 |
| Data/restrains/ parameters | 3375/3/201 |
| Final R indices [I > 2 |
|
| R indices (all data) |
|
Selected bond lengths (Å) and bond angles (°) of ligand [H2dampt] (1).
| Bond lengths (Å) | |||
|---|---|---|---|
| S1–C9 | 1.694 (3) | O1–C1 | 1.357 (4) |
| N1–C7 | 1.295 (4) | N1–N2 | 1.375 (3) |
| N2–C9 | 1.352 (4) | N3–C9 | 1.344 (3) |
| C7–C8 | 1.500 (4) | C6–C7 | 1.473 (4) |
|
| |||
| Bond angles (°) | |||
|
| |||
| C7–N1–N2 | 119.0 (2) | C9–N2–N1 | 120.6 (2) |
| C9–N3–C10 | 127.7 (2) | N3–C9–N2 | 113.2 (2) |
| N3–C9–S1 | 124.3 (2) | N2–C9–S1 | 122.4 (2) |
| O1–C1–C2 | 116.8 (3) | O1–C1–C6 | 123.2 (3) |
Hydrogen-bond geometry (Å, °)
|
|
| H··· |
|
|
|---|---|---|---|---|
| O1–H1o···N1 | 0.84 (1) | 1.81 (2) | 2.551 (3) | 145 (3) |
| N2–H2n···S1i | 0.88 (1) | 2.51 (2) | 3.323 (2) | 154 (3) |
| N3–H3n···S1i | 0.88 (1) | 2.49 (2) | 3.286 (3) | 151 (2) |
| C8–H8b···Cg1i | 0.98 | 2.59 | 3.501 (3) | 155 |
| Symmetry codes: | ||||
Figure 2A view of the helical supramolecular chain aligned along the b axis in (I). The N–H···S hydrogen bonds are shown as orange dashed lines. Further stabilization to the chain is provided by C–H···π and π–π interactions, shown as blue and purple dashed lines, respectively.
Antibacterial activitya,b of the free ligand (1) and its organotin(IV) complexes 2–6 (inhibition zone in mm).
| Bacterium | Clinical implication | Zone of Inhibition (mm) | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||
|
| Infection of wounds, urinary tract, and dysentery | 24 | 12 | 20 | 21 | 28 | 29 | 34 |
|
| Food poisoning, scaled skin syndrome, endocarditis | 14 | 22 | 24 | — | 29 | 30 | 36 |
|
| Lower respiratory tract infections, skin and soft-tissue infections | — | — | 20 | 22 | 20 | 22 | 26 |
|
| Typhoid fever, localized infection | 21 | — | 14 | 23 | 23 | 27 | 31 |
a In vitro, agar-well diffusion method, conc. 200 mg/mL of DMSO. bReference drug (R), doxycycline, dash indicate inactivity.
Figure 3Antibacterial activity of compounds 1–6 against various bacteria.